Showing results (1-10 of 10) with videos related to

Sort By:
Pageof 1
Duodecim; Laaketieteellinen Aikakauskirja|September 14, 2012
[Primary biliary cirrhosis (PBC)]Henna Rautiainen
Liver International : Official Journal of the International Association for the Study of the Liver|April 10, 2008
Serological markers for monitoring disease progression in noncirrhotic primary biliary cirrhosis on ursodeoxycholic acid therapyMartti Färkkilä, Henna Rautiainen, Päivi Kärkkäinen, et al.
Hepatology (Baltimore, Md.)|March 9, 2005
Budesonide combined with UDCA to improve liver histology in primary biliary cirrhosis: a three-year randomized trialHenna Rautiainen, Päivi Kärkkäinen, A-L Karvonen, et al.
Scandinavian Journal of Gastroenterology|October 6, 2007
Prevalence and incidence of primary biliary cirrhosis are increasing in FinlandHenna Rautiainen, Veikko Salomaa, Seppo Niemelå, et al.
Scandinavian Journal of Gastroenterology|April 24, 2012
Fecal calprotectin and S100A12 have low utility in prediction of small bowel Crohn's disease detected by wireless capsule endoscopyTaina Sipponen, Johanna Haapamäki, Erkki Savilahti, et al.
Journal of Crohn'S & Colitis|November 28, 2012
Achievement of deep remission during scheduled maintenance therapy with TNFα-blocking agents in IBDPauliina Molander, Taina Sipponen, Helena Kemppainen, et al.
Inflammatory Bowel Diseases|May 7, 2014
Outcome after discontinuation of TNFα-blocking therapy in patients with inflammatory bowel disease in deep remissionPauliina Molander, Martti Färkkilä, Kimmo Salminen, et al.
Journal of Crohn'S & Colitis|July 24, 2014
Does fecal calprotectin predict short-term relapse after stopping TNFα-blocking agents in inflammatory bowel disease patients in deep remission?Pauliina Molander, Martti Färkkilä, Ari Ristimäki, et al.
Scandinavian Journal of Gastroenterology|December 21, 2017
High treatment persistence rate and significant endoscopic healing among real-life patients treated with vedolizumab - a Finnish Nationwide Inflammatory Bowel Disease Cohort Study (FINVEDO)Tero Ylisaukko-Oja, Jaakko Aaltonen, Heikki Nuutinen, et al.
Biologicals : Journal of the International Association of Biological Standardization|February 14, 2019
Characterization of inflammatory bowel disease management by vedolizumab and concomitant treatments in real-life clinical practiceTero Ylisaukko-Oja, Saku Torvinen, Jaakko Aaltonen, et al.
Pageof 1